Article
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
Alimentary pharmacology & therapeutics - 15 Feb 2005
Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S
Abstract excerpt
BACKGROUND: Proton-pump inhibitors, such as lansoprazole, are metabolized in the liver by CYP2C19 and cannot inhibit acid sufficiently in homozygous extensive metabolizers of CYP2C19. AIM: To examine whether famotidine would increase the cure rates of Helicobacter pylori infection by a standard triple therapy. METHODS: A total of 177 H. pylori-positive patients were randomly assigned to either lansoprazole 30 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.